Jan 8 (Reuters) - Eli Lilly (LLY.N), opens new tab said on Thursday a late-stage trial showed its weight-loss drug Zepbound, used with its psoriatic arthritis treatment Taltz, improved arthritis ...
At 36 weeks, the TOGETHER-PsA study met its primary endpoint of 50% improvement in psoriatic arthritis (PsA) activity based on ACR50 in addition to ≥10% weight reduction with concomitant Taltz and ...
As evidence of tirzepatide’s efficacy mounts across a range of cardiometabolic conditions, Eli Lilly has shown that taking the incretin medicine alongside another of its drugs, Taltz, could lead to ...
Patients given a combination of Eli Lilly & Co.’s weight-loss shot Zepbound and arthritis drug Taltz saw a greater improvement in tender and swollen joints compared to those on Taltz alone, a new ...
Eli Lilly logo is shown on one of the company's offices in San Diego, California, U.S., September 17, 2020. REUTERS/Mike Blake Jan 8 (Reuters) - Eli Lilly said on Thursday a late-stage trial showed ...
Eli Lilly’s best-selling weight loss drug, Zepbound (tirzepatide), has scored again, this time in a late-stage trial alongside the company’s plaque psoriasis drug, Taltz (ixekizumab). During the Phase ...
INDIANAPOLIS - Eli Lilly and Company (NYSE:LLY) announced Thursday that its Phase 3b TOGETHER-PsA trial met its primary endpoint, showing that concomitant use of Taltz (ixekizumab) and Zepbound ...
On Thursday, Eli Lilly and Co. (NYSE: LLY) revealed topline results from the novel TOGETHER-PsA open-label Phase 3b trial evaluating the concomitant use of Taltz (ixekizumab) and Zepbound (tirzepatide ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback